Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with prostate cancer (a specific type called adenocarcinoma, confirmed by a tissue sample reviewed by a central laboratory)
- People whose prostate cancer is classified as "low risk" — meaning the cancer is at an early, localised stage (T1–T2b), has a Grade Group of 1, and a PSA blood test result below 10 ng/ml
- People whose prostate cancer is classified as "favourable intermediate risk" — meaning only one of the following applies: the cancer is slightly more localised (stage cT2c), OR has a Grade Group of 2, OR has a PSA between 10–20 ng/ml
- People whose prostate cancer has a Grade Group of 3, a PSA below 20 ng/ml, a stage below cT2c, and less than 10% of the cancer showing a more aggressive pattern (confirm with trial site)
Who may not be able to join:
- People who are receiving or planning to receive hormone therapy to lower testosterone (such as LHRH-agonists or anti-androgen medications)
- People who have previously had radiation therapy to the pelvic area
- People taking blood-thinning medications that cannot safely be stopped for a minor procedure to insert small gold markers into the prostate
- People who have a diagnosed condition that affects normal blood clotting
- People whose prostate is larger than 90 cubic centimetres, as shown on medical imaging
- People who are taking medications that suppress the immune system
- People who have inflammatory bowel disease
- People who have artificial implants in both hips
- People who are unable to have an MRI scan for any reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Danny Vesprini, MD, Sunnybrook Health Sciences Centre
Phone: 416-480-6100
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Prostate Cancer Patient's Quality of Life Function will be measured to determine change in Quality of life function from baseline to 5 years beyond treatment.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.